Recent patents on rheumatoid arthritis, cancer and schizophrenia theranostics

Highlights of recent US patent applications

1. Externalized phoshatidylserine as a global tumor blood vessel biomarker and a cancer theranostics target
   
2. PDE10 inhibitors for schizophrenia theranostics
3. Antibodies that specifically inhibit VEGF binding to VEGFR2 receptors for cancer theranostics
4. Radiolabeled cyclic pentapeptide drug for the diagnosis and treatment (theranostics) of cancer
5. T cells expressing B-Raf and K-Ras for rheumatoid arthritis theranostics (diagnostic therapy)
6. Phosphodiesterase 4D7 (PDE4D7) for prostate cancer theransotics (diagnostics therapy)
7. Phosphodiesterase 9A (PDE9A) for prostate cancer theransotics (diagnostics therapy)

Details: http://www.sciclips.com/sciclips/biomarker-news.do